BridgeBio Pharma (NASDAQ:BBIO) Releases Earnings Results, Misses Expectations By $0.14 EPS

Key Points

• BridgeBio missed Q1 EPS expectations, reporting ($0.84) vs. the ($0.70) consensus (a $0.14 miss), but revenue beat at $194.5M—up 66.8% YoY—driven largely by Attruby, which generated $180.6M in U.S. net product revenue (24% QoQ, 392% YoY) and showed emerging clinical differentiation versus tafamidis.
• The board authorized a $500 million share repurchase program while emphasizing opportunistic buybacks and preserving capital for launches; BridgeBio ended the quarter with $940.2M in cash and marketable securities, a narrowing Q1 operating loss of $106M, and guidance toward P&L breakeven and sustainable cash flow by/after 2027.
• BBIO shares traded down about 0.9% to $67.45 after the print, and the street consensus remains a "Moderate Buy" with a $87.71 average price target from analysts.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) posted its earnings results on Thursday. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.14), FiscalAI reports. The firm had revenue of $194.52 million for the quarter, compared to the consensus estimate of $178.64 million. During the same period in the prior year, the company posted ($0.88) EPS. The company's revenue for the quarter was up 66.8% compared to the same quarter last year.

Here are the key takeaways from BridgeBio Pharma's conference call:

• Attruby (acoramidis) delivered $180.6 million in U.S. net product revenue in Q1 (24% QoQ, 392% YoY), with accelerating front‑line share and emerging real‑world evidence showing clinical differentiation versus tafamidis (including reduced diuretic intensification and signals of lower acute kidney injury and mortality).
• BridgeBio is preparing three near‑term launches (LGMD2I/BBP‑418, ADH1/encaleret, and achondroplasia/infigratinib) with rapid NDA submission for LGMD2I, active patient‑identification efforts (≈2,000 ADH1 candidates by claims), and strong commercial readiness and early awareness for infigratinib.
• The board authorized a $500 million share repurchase program to address a perceived disconnect between intrinsic value and market price, while management says repurchases will be opportunistic and preserve capital for launches and development.
• Q1 results show revenue growth (total revenue $194.5M) driven by Attruby, an improving operating loss trajectory (Q1 operating loss $106M, narrowing over recent quarters), and a strong liquidity position ($940.2M in cash and marketable securities) with guidance toward P&L breakeven and sustainable cash flow positivity by and after 2027.

BridgeBio Pharma Stock Down 0.9%

Shares of BBIO stock traded down $0.64 during trading hours on Thursday, hitting $67.45. 2,866,078 shares of the company's stock traded hands, compared to its average volume of 2,700,602. The stock's fifty day simple moving average is $71.27 and its two-hundred day simple moving average is $71.32. BridgeBio Pharma has a 12-month low of $31.77 and a 12-month high of $84.94. The stock has a market cap of $13.21 billion, a price-to-earnings ratio of -17.84 and a beta of 1.02.

Analyst Ratings Changes

BBIO has been the subject of several research analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. Barclays restated an "overweight" rating on shares of BridgeBio Pharma in a report on Tuesday, March 10th. Raymond James Financial set a $89.00 price objective on shares of BridgeBio Pharma and gave the stock an "outperform" rating in a report on Thursday, February 12th. Truist Financial raised their price objective on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the stock a "buy" rating in a report on Wednesday, April 29th. Finally, Mizuho restated an "outperform" rating and issued a $106.00 price objective on shares of BridgeBio Pharma in a report on Tuesday, April 28th. Twenty-four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $87.71.

Insider Activity

In other news, CAO Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $71.58, for a total transaction of $143,160.00. Following the completion of the transaction, the chief accounting officer directly owned 134,115 shares in the company, valued at approximately $9,599,951.70. This trade represents a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Thomas Trimarchi sold 13,600 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $74.72, for a total transaction of $1,016,192.00. Following the transaction, the chief financial officer owned 336,585 shares of the company's stock, valued at $25,149,631.20. The trade was a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 239,084 shares of company stock valued at $16,777,579. 14.23% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BridgeBio Pharma

Large investors have recently made changes to their positions in the business. Global Retirement Partners LLC lifted its holdings in shares of BridgeBio Pharma by 271.5% during the fourth quarter. Global Retirement Partners LLC now owns 509 shares of the company's stock valued at $39,000 after purchasing an additional 372 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new position in BridgeBio Pharma in the 4th quarter worth approximately $41,000. Harvest Fund Management Co. Ltd purchased a new position in BridgeBio Pharma in the 3rd quarter worth approximately $34,000. Smartleaf Asset Management LLC raised its holdings in BridgeBio Pharma by 63.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 739 shares of the company's stock worth $56,000 after acquiring an additional 286 shares during the last quarter. Finally, Jones Financial Companies Lllp purchased a new position in BridgeBio Pharma in the 1st quarter worth approximately $35,000. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.